Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Linda Ochieng

Physician Assistant Fort Worth, TX Physician Assistant

NPI 1851769095 CMS profile 11120666

1217 Grand Ave, Fort Worth, TX 76164

Open in the dashboard

General payments

$8,333

468 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Linda Ochieng of Fort Worth, TX is reported in the CMS Open Payments database as having received $8,333 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,239 59
2024 General $1,403 70
2023 General $1,519 95
2022 General $1,749 117
2021 General $2,422 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linda Ochieng
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Linda Ochieng were reported at $1,239. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Linda Ochieng Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,422 $132 $37–$438 $132
2022 $1,749 $155 $48–$522 $149
2023 $1,519 $167 $52–$557 $160
2024 $1,403 $178 $55–$600 $164
2025 $1,239 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $976 73 payments
  2. AstraZeneca Pharmaceuticals LP $888 37 payments
  3. Corcept Therapeutics $689 23 payments
  4. Lilly USA, LLC $629 39 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $446 28 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $436 27 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $325 22 payments
  8. GlaxoSmithKline, LLC. $309 19 payments
  9. OptiNose US, Inc. $300 17 payments
  10. Amarin Pharma Inc. $233 13 payments
  11. Other $3,101 170 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,313 467 payments
  2. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $876 66 payments
  2. Korlym $689 23 payments
  3. RYBELSUS $677 61 payments
  4. FARXIGA $499 21 payments
  5. XIFAXAN $446 28 payments
  6. TRULANCE $376 24 payments
  7. MOUNJARO $336 18 payments
  8. BREZTRI $334 13 payments
  9. Kerendia $325 22 payments
  10. JARDIANCE $316 20 payments
  11. Other $5,342 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record